Research Strategy & Impact

On this page

Myeloma Canada Aurelia Initiative

Funding Myeloma Research

Myeloma Canada’s Aurelia Research Grants fund innovative, patient-centred research that targets the most pressing gaps in diagnosis, treatment, and scientific understanding. We’re transforming commitment into impact — improving lives, extending survival, and accelerating progress toward a cure.

In 2025, Myeloma Canada supported…

16

Canadian investigators

10

research projects

8

emerging myeloma researchers

Since 2011, over $9M has been invested in myeloma research.

Research Priorities that Matter Most to the Community

We believe the best research starts by listening to those most affected. That’s why we asked people living with myeloma, their caregivers, and the healthcare professionals who support them to tell us what research they feel is most important. This national priority-setting process helped ensure that the research we fund truly reflects the needs and experiences of the Canadian myeloma community.

Together, they identified the top 10 research priorities, which now guide all our funding decisions. These priorities focus on the areas that can make the biggest difference in the lives of patients and their families.

These Priorities Include:

Finding a cure
Advancing immunotherapies
Improving early diagnosis
Personalizing treatment
Reducing treatment side effects
Enhancing quality-of-life
Addressing bone damage
Managing drug resistance and relapsed disease
Supporting high-risk patients
Improving access and equity across the healthcare system

Read the peer-reviewed article in the British Journal of Haematology

Our Funding Model

Myeloma Canada funds important, life-changing research thanks to generous community fundraising, donations, and partnerships with organizations that share our goals.

To make sure every dollar goes to the most promising and meaningful projects, all research proposals go through a careful and fair review process. This process follows global best practices to ensure transparency and integrity.

Each application is reviewed by Myeloma Canada’s Independent Research Review Committee (IRRC), which includes healthcare professionals, scientists, and people personally affected by myeloma.

The IRRC looks at:

How well the project addresses our top research priorities
The strength and originality of the science
Whether the project is realistic, likely to make a difference, and meaningfully includes patients

Progress Reporting: Transparency and Accountability

All funded researchers must submit interim and final progress reports to track milestones and ensure transparency for our community, donors, and partners.